Targeting IRAK1 as a therapeutic approach for Myelodysplastic Syndrome

Myelodysplastic Syndromes (MDS) arise from a defective hematopoietic stem/progenitor cell. Consequently, there is an urgent need to develop targeted therapies capable of eliminating the MDS-initiating clones. We identified that IRAK1, an immune modulating kinase, is overexpressed and hyperactivated...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Rhyasen, Garrett W., Bolanos, Lyndsey, Fang, Jing, Jerez, Andres, Wunderlich, Mark, Rigolino, Carmela, Mathews, Lesley, Ferrer, Marc, Southall, Noel, Guha, Rajarshi, Keller, Jonathan, Thomas, Craig, Beverly, Levi J., Cortelezzi, Agostino, Oliva, Esther N., Cuzzola, Maria, Maciejewski, Jaroslaw P., Mulloy, James C., Starczynowski, Daniel T.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3711103/
https://ncbi.nlm.nih.gov/pubmed/23845443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccr.2013.05.006
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars